Specifically, patients with COPD often exhibit increased PD-L1 expression on tumor cells and elevated tumor mutational burden (TMB), both established biomarkers of ICI responsiveness [17, 19]. This evidence concerns the gene CD274 and chronic obstructive pulmonary disease.